JenYii的个人主页 - 老虎社区

JenYii

JenYii

暂无个人介绍

IP属地：未知

331关注

12粉丝

0主题

0勋章

2021-04-20

Comment and like, pls.

抱歉，原内容已删除

2021-08-09

Like & comment, please………👆🏻🙏🏻

BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid

2021-08-01

Like & comment, please………….👆🏻🙏🏻

抱歉，原内容已删除

2021-07-31

Please like ……….………………….👆🏻🙏🏻

抱歉，原内容已删除

2021-04-24

Like and comment pls

Why AMD Stock Popped After Intel's Earnings Beat

2021-08-08

Like & comment, please………👆🏻🙏🏻

SEC Moves First DeFi Unregistered Securities Lawsuit

2021-08-01

Please like and comment 🙏🏻

抱歉，原内容已删除

2021-04-15

It’s temporary 🦾

抱歉，原内容已删除

2021-12-06

Ok

Why Moderna Is the Biggest Winner From COVID Boosters So Far

2021-04-05

[得意] [财迷] [笑哭]

2021-02-15

Hope it happens

抱歉，原内容已删除

2021-04-15

Pls help comment and like 🙏🏻

抱歉，原内容已删除

2021-03-18

Way to go!

Legend Biotech EPS beats by $0.08, beats on revenue

2021-02-23

[流泪]

Why Tesla Stock Fell Sharply on Monday

2021-02-15

Useful

抱歉，原内容已删除

2021-06-20

🙏🏻🙏🏻🙏🏻

2021-06-18

Read the safety before flying to the moon 🚀🚀🚀

2021-06-17

一分一毫清清楚楚

2021-06-16

Lastly, buy!

2021-06-14

🙏🏻🙏🏻🙏🏻

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3559395309338899","uuid":"3559395309338899","gmtCreate":1596349342614,"gmtModify":1612695532145,"name":"JenYii","pinyin":"jenyii","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":12,"headSize":331,"tweetSize":38,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.73%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.07","exceedPercentage":"80.84%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":608534193,"gmtCreate":1638756985400,"gmtModify":1638756985492,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608534193","repostId":"1125593879","repostType":4,"isVote":1,"tweetType":1,"viewCount":2776,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":898497158,"gmtCreate":1628516416674,"gmtModify":1631889789540,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Like &amp; comment, please………👆🏻🙏🏻","listText":"Like &amp; comment, please………👆🏻🙏🏻","text":"Like & comment, please………👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/898497158","repostId":"2158238441","repostType":4,"repost":{"id":"2158238441","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1628514928,"share":"https://www.laohu8.com/m/news/2158238441?lang=&edition=full","pubTime":"2021-08-09 21:15","market":"us","language":"en","title":"BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid","url":"https://stock-news.laohu8.com/highlight/detail?id=2158238441","media":"Investors","summary":"BioNTech stock popped on Monday after reporting adjusted profit of $12.67 a share on $6.24 billion in second-quarter sales.","content":"<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p>\n<p>Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p>\n<p>In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p>\n<p>BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p>\n<p>In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-08-09 21:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p>\n<p>Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p>\n<p>In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p>\n<p>BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p>\n<p>In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158238441","content_text":"BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.\nAnalysts polled by FactSet expected BioNTech to earn $8.87 per share on $3.83 billion in sales.\nIn the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.\nBioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the Pfizer partner to earn $33.12 a share on $14.68 billion in sales.\nIn premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.","news_type":1,"symbols_score_info":{"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":1629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891650118,"gmtCreate":1628388100434,"gmtModify":1631889789559,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Like &amp; comment, please………👆🏻🙏🏻","listText":"Like &amp; comment, please………👆🏻🙏🏻","text":"Like & comment, please………👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/891650118","repostId":"1180529438","repostType":4,"repost":{"id":"1180529438","kind":"news","pubTimestamp":1628386129,"share":"https://www.laohu8.com/m/news/1180529438?lang=&edition=full","pubTime":"2021-08-08 09:28","market":"us","language":"en","title":"SEC Moves First DeFi Unregistered Securities Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=1180529438","media":"Benzinga","summary":"The United States Securities and Exchange Commission  sued the organization responsible for the development of a decentralized finance  protocol over activities involved with the project for the first time.What Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purported","content":"<div>\n<p>The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">Web Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SEC Moves First DeFi Unregistered Securities Lawsuit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSEC Moves First DeFi Unregistered Securities Lawsuit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-08 09:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180529438","content_text":"The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project for the first time.\nWhat Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purportedly sold over $30 million worth of two types of tokens that the SEC deemed to be securities that should have been registered as such.\nThe SEC notes that Blockchain Credit Partners founders Gregory Keough and Derek Acree will have to pay fines of $125,000 while the company itself also agreed to pay $12.8 million in disgorgement. The settlement does not indicate an admition or denial the accusations.\nNew Game, Old Rules?\nSEC Enforcement Director Gurbir Grewal explained that \"full and honest disclosure remains the cornerstone of our securities laws — no matter what technologies are used to offer and sell those securities.\" This comment makes it very clear that slapping the DeFi label on a project and hoping to avoid regulation this way works no better than calling it a \"utility token\" prevented falling under the SEC's scrutiny during 2017's initial coin offering craze.\nThe SEC is trying to send the clear rule that the new kind of financial organizations that operate on blockchains have to still play by the old rules that govern traditional finance. At the same time, market onlookers are not sure if the regulator is actually right.\nIn a way, it is a tour de force where the regulator wins every time it has a way to take enforcement action, but these new organizations potentially have a very real way to make enforcement impossible — or at the very least impractical. The only protection against enforcement by the SEC and other regulators is decentralization and the only reason why the SEC was able to act in this case is that a centralized organization such as Blockchain Credit Partners exists.\nWhat's Next:If no company exists and all that there is to a DeFi protocol is a set of smart contracts deployed on a blockchain by a group of anonymous developers scattered around the world there is very little that the SEC can do short of attacking the blockchain itself. This is where the decentralization of the underlying blockchain comes into play: will the regulators for instance be able to force Ethereum's (CRYPTO: ETH) core development team to write an update stopping such a project?\nIf the regulators would actually be able to force the blockchain's developers to write such an update, would node operators and miners or stakers adopt this software or would they refuse to? Such situations will be the real test of the decentralization and reliability of any blockchain that many are waiting to happen. Regulators are seeing power slipping away between their fingers like sand, and they are going to try to grab it.","news_type":1,"symbols_score_info":{"COIN":0.9}},"isVote":1,"tweetType":1,"viewCount":1476,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802510374,"gmtCreate":1627787223898,"gmtModify":1631889789570,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Please like and comment 🙏🏻","listText":"Please like and comment 🙏🏻","text":"Please like and comment 🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/802510374","repostId":"1159296868","repostType":4,"isVote":1,"tweetType":1,"viewCount":1482,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802534082,"gmtCreate":1627787044146,"gmtModify":1631889789579,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Like &amp; comment, please………….👆🏻🙏🏻","listText":"Like &amp; comment, please………….👆🏻🙏🏻","text":"Like & comment, please………….👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/802534082","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":1421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802379206,"gmtCreate":1627725322505,"gmtModify":1631889789594,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Please like ……….………………….👆🏻🙏🏻","listText":"Please like ……….………………….👆🏻🙏🏻","text":"Please like ……….………………….👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/802379206","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":1787,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164051645,"gmtCreate":1624162333087,"gmtModify":1631889789608,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"🙏🏻🙏🏻🙏🏻","listText":"🙏🏻🙏🏻🙏🏻","text":"🙏🏻🙏🏻🙏🏻","images":[{"img":"https://static.tigerbbs.com/d8dd96436bea0b9c92dd95ae16e70361","width":"1125","height":"1074"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164051645","isVote":1,"tweetType":1,"viewCount":1687,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":166010936,"gmtCreate":1623985232225,"gmtModify":1631889789623,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Read the safety before flying to the moon 🚀🚀🚀","listText":"Read the safety before flying to the moon 🚀🚀🚀","text":"Read the safety before flying to the moon 🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/bf7f199d98279f47b434137f93979947","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166010936","isVote":1,"tweetType":1,"viewCount":1216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":161971406,"gmtCreate":1623902995605,"gmtModify":1631889789642,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"一分一毫 清清楚楚","listText":"一分一毫 清清楚楚","text":"一分一毫 清清楚楚","images":[{"img":"https://static.tigerbbs.com/2df10f85bb15a2fd54fd84fa66c51782","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161971406","isVote":1,"tweetType":1,"viewCount":1949,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":169061156,"gmtCreate":1623809414075,"gmtModify":1631889789654,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Lastly, buy!","listText":"Lastly, buy!","text":"Lastly, buy!","images":[{"img":"https://static.tigerbbs.com/977ef722d3398baaae16beac29e882c8","width":"720","height":"720"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169061156","isVote":1,"tweetType":1,"viewCount":1279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":185908820,"gmtCreate":1623629234460,"gmtModify":1631889789662,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"🙏🏻🙏🏻🙏🏻","listText":"🙏🏻🙏🏻🙏🏻","text":"🙏🏻🙏🏻🙏🏻","images":[{"img":"https://static.tigerbbs.com/810dfc226dde7db2efc68b3b69c713e8","width":"1125","height":"1100"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185908820","isVote":1,"tweetType":1,"viewCount":645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":181470501,"gmtCreate":1623409319803,"gmtModify":1631893519110,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"🤨🤨🤨","listText":"🤨🤨🤨","text":"🤨🤨🤨","images":[{"img":"https://static.tigerbbs.com/9eef982044c1a06f12729586b864c505","width":"1125","height":"1285"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/181470501","isVote":1,"tweetType":1,"viewCount":483,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":130445533,"gmtCreate":1621563060522,"gmtModify":1631893519123,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"[Cool]&nbsp;[Cool]&nbsp;[Cool]&nbsp;","listText":"[Cool]&nbsp;[Cool]&nbsp;[Cool]&nbsp;","text":"[Cool] [Cool] [Cool]","images":[{"img":"https://static.tigerbbs.com/2df10f85bb15a2fd54fd84fa66c51782","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/130445533","isVote":1,"tweetType":1,"viewCount":543,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":194793896,"gmtCreate":1621398562015,"gmtModify":1631893519136,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"💭💭💭","listText":"💭💭💭","text":"💭💭💭","images":[{"img":"https://static.tigerbbs.com/1b3ccf6b25ac96098455b733bacbd848","width":"1125","height":"1088"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/194793896","isVote":1,"tweetType":1,"viewCount":519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":196523017,"gmtCreate":1621077977139,"gmtModify":1631893519150,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"The choice is yours","listText":"The choice is yours","text":"The choice is yours","images":[{"img":"https://static.tigerbbs.com/9a8a9e98db8fbea1332f77480b0b2c81","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/196523017","isVote":1,"tweetType":1,"viewCount":368,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":198862076,"gmtCreate":1620951484695,"gmtModify":1631893519163,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Putting money&nbsp;in a&nbsp;bank or&nbsp;buying the bank shares?","listText":"Putting money&nbsp;in a&nbsp;bank or&nbsp;buying the bank shares?","text":"Putting money in a bank or buying the bank shares?","images":[{"img":"https://static.tigerbbs.com/314825c21655ba8acbb27c7862fd8bac","width":"1125","height":"1070"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/198862076","isVote":1,"tweetType":1,"viewCount":472,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":190589276,"gmtCreate":1620633955095,"gmtModify":1631893519172,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Fun fact","listText":"Fun fact","text":"Fun fact","images":[{"img":"https://static.tigerbbs.com/83b46f142a59c6b2396226c8f3fa469f","width":"1125","height":"602"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/190589276","isVote":1,"tweetType":1,"viewCount":352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":107405123,"gmtCreate":1620526651362,"gmtModify":1631893519186,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"母亲节快乐 !&nbsp;Happy Mother’s Day !🤎♥️❤️🧡💛💚💙💜🤍","listText":"母亲节快乐 !&nbsp;Happy Mother’s Day !🤎♥️❤️🧡💛💚💙💜🤍","text":"母亲节快乐 ! Happy Mother’s Day !🤎♥️❤️🧡💛💚💙💜🤍","images":[{"img":"https://static.tigerbbs.com/985b573fdaca436c795639ecd2b065c5","width":"1125","height":"1283"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/107405123","isVote":1,"tweetType":1,"viewCount":2146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":105023023,"gmtCreate":1620260353262,"gmtModify":1631893519201,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"😎🥸🤓","listText":"😎🥸🤓","text":"😎🥸🤓","images":[{"img":"https://static.tigerbbs.com/df01411b4c036f7e0ec35d5c2817f27d","width":"1125","height":"1260"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/105023023","isVote":1,"tweetType":1,"viewCount":474,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":102897280,"gmtCreate":1620191147440,"gmtModify":1631893519209,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Educated&nbsp;them for what they are not learning in school","listText":"Educated&nbsp;them for what they are not learning in school","text":"Educated them for what they are not learning in school","images":[{"img":"https://static.tigerbbs.com/9ffffddc61e04d0a9b36583a41f7c78d","width":"1125","height":"1110"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102897280","isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":373744064,"gmtCreate":1618887249158,"gmtModify":1634290127183,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Comment and like, pls.","listText":"Comment and like, pls.","text":"Comment and like, pls.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/373744064","repostId":"2128689062","repostType":4,"isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898497158,"gmtCreate":1628516416674,"gmtModify":1631889789540,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Like &amp; comment, please………👆🏻🙏🏻","listText":"Like &amp; comment, please………👆🏻🙏🏻","text":"Like & comment, please………👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/898497158","repostId":"2158238441","repostType":4,"repost":{"id":"2158238441","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1628514928,"share":"https://www.laohu8.com/m/news/2158238441?lang=&edition=full","pubTime":"2021-08-09 21:15","market":"us","language":"en","title":"BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid","url":"https://stock-news.laohu8.com/highlight/detail?id=2158238441","media":"Investors","summary":"BioNTech stock popped on Monday after reporting adjusted profit of $12.67 a share on $6.24 billion in second-quarter sales.","content":"<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p>\n<p>Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p>\n<p>In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p>\n<p>BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p>\n<p>In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-08-09 21:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p>\n<p>Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p>\n<p>In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p>\n<p>BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p>\n<p>In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158238441","content_text":"BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.\nAnalysts polled by FactSet expected BioNTech to earn $8.87 per share on $3.83 billion in sales.\nIn the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.\nBioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the Pfizer partner to earn $33.12 a share on $14.68 billion in sales.\nIn premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.","news_type":1,"symbols_score_info":{"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":1629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802534082,"gmtCreate":1627787044146,"gmtModify":1631889789579,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Like &amp; comment, please………….👆🏻🙏🏻","listText":"Like &amp; comment, please………….👆🏻🙏🏻","text":"Like & comment, please………….👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/802534082","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":1421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802379206,"gmtCreate":1627725322505,"gmtModify":1631889789594,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Please like ……….………………….👆🏻🙏🏻","listText":"Please like ……….………………….👆🏻🙏🏻","text":"Please like ……….………………….👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/802379206","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":1787,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375007723,"gmtCreate":1619252337662,"gmtModify":1631893519229,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/375007723","repostId":"1180713929","repostType":4,"repost":{"id":"1180713929","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1619191972,"share":"https://www.laohu8.com/m/news/1180713929?lang=&edition=full","pubTime":"2021-04-23 23:32","market":"us","language":"en","title":"Why AMD Stock Popped After Intel's Earnings Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1180713929","media":"Tiger Newspress","summary":"Here's a hint: It's not because Intel reported great news.What happenedShares of rising Intel (NASDA","content":"<p>Here's a hint: It's not because Intel reported great news.</p><p><b>What happened</b></p><p>Shares of rising&nbsp;<b>Intel</b>&nbsp;(NASDAQ:INTC)&nbsp;rival and fellow&nbsp;semiconductors&nbsp;giant&nbsp;<b>Advanced Micro Devices</b>&nbsp;(NASDAQ:AMD)&nbsp;popped in early trading on the Nasdaq Friday, the first day afterIntel's disappointing Q1 2021 earnings report. AMD's shares were up 4.5% as of 11:30 a.m. EDT.</p><p><img src=\"https://static.tigerbbs.com/368e9bc79febd0164dab4a88ffd13c42\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/cf04377bf945cfdaa9a52157bb5560f7\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p></p><p><b>So what</b></p><p>Intel, if you haven't heard, actually&nbsp;beat&nbsp;on its Q1 earnings. Despite sales declining 1% year over year, the company managed to report a pro forma profit of $1.39 per share, which was ahead of analyst expectations.</p><p>Regardless, Intel reported a steep 540 basis point decline in its gross margin to 55.2%, and it saw its operating margin cut nearly in half as the company spent heavily to race to catch up to its rivals in advanced computer chips. Analysts at Citigroup commented yesterday that Intel stock appears to be close to its peak valuation and is likely to decline as investors acclimate to the new environment in which Intel is losing, not gaining, market share.</p><p>And the reason this is good news for&nbsp;AMD&nbsp;is that, according to Citi at least, it's AMD that's taking that market share away from Intel.</p><p><b>Now what</b></p><p>So what's an investor to do with all this information?</p><p>At a valuation of just 13.6 times trailing earnings, Intel stock certainly looks like a relative bargain when compared with AMD stock, which trades at 38.4 times earnings. But AMD has acash-rich balance sheet, versus Intel that's carrying $13.5 billion in net debt. And analysts see Intel's earnings growing only 10% annually over the next five years, while AMD is pegged for 29.5% annualized earnings growth, according toS&amp;P Global Market Intelligencedata.</p><p>Intel may&nbsp;look&nbsp;like&nbsp;a value stockright now, but it's AMD that's gotall the momentum.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why AMD Stock Popped After Intel's Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy AMD Stock Popped After Intel's Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-04-23 23:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Here's a hint: It's not because Intel reported great news.</p><p><b>What happened</b></p><p>Shares of rising&nbsp;<b>Intel</b>&nbsp;(NASDAQ:INTC)&nbsp;rival and fellow&nbsp;semiconductors&nbsp;giant&nbsp;<b>Advanced Micro Devices</b>&nbsp;(NASDAQ:AMD)&nbsp;popped in early trading on the Nasdaq Friday, the first day afterIntel's disappointing Q1 2021 earnings report. AMD's shares were up 4.5% as of 11:30 a.m. EDT.</p><p><img src=\"https://static.tigerbbs.com/368e9bc79febd0164dab4a88ffd13c42\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/cf04377bf945cfdaa9a52157bb5560f7\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p></p><p><b>So what</b></p><p>Intel, if you haven't heard, actually&nbsp;beat&nbsp;on its Q1 earnings. Despite sales declining 1% year over year, the company managed to report a pro forma profit of $1.39 per share, which was ahead of analyst expectations.</p><p>Regardless, Intel reported a steep 540 basis point decline in its gross margin to 55.2%, and it saw its operating margin cut nearly in half as the company spent heavily to race to catch up to its rivals in advanced computer chips. Analysts at Citigroup commented yesterday that Intel stock appears to be close to its peak valuation and is likely to decline as investors acclimate to the new environment in which Intel is losing, not gaining, market share.</p><p>And the reason this is good news for&nbsp;AMD&nbsp;is that, according to Citi at least, it's AMD that's taking that market share away from Intel.</p><p><b>Now what</b></p><p>So what's an investor to do with all this information?</p><p>At a valuation of just 13.6 times trailing earnings, Intel stock certainly looks like a relative bargain when compared with AMD stock, which trades at 38.4 times earnings. But AMD has acash-rich balance sheet, versus Intel that's carrying $13.5 billion in net debt. And analysts see Intel's earnings growing only 10% annually over the next five years, while AMD is pegged for 29.5% annualized earnings growth, according toS&amp;P Global Market Intelligencedata.</p><p>Intel may&nbsp;look&nbsp;like&nbsp;a value stockright now, but it's AMD that's gotall the momentum.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司","INTC":"英特尔"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180713929","content_text":"Here's a hint: It's not because Intel reported great news.What happenedShares of rising Intel (NASDAQ:INTC) rival and fellow semiconductors giant Advanced Micro Devices (NASDAQ:AMD) popped in early trading on the Nasdaq Friday, the first day afterIntel's disappointing Q1 2021 earnings report. AMD's shares were up 4.5% as of 11:30 a.m. EDT.So whatIntel, if you haven't heard, actually beat on its Q1 earnings. Despite sales declining 1% year over year, the company managed to report a pro forma profit of $1.39 per share, which was ahead of analyst expectations.Regardless, Intel reported a steep 540 basis point decline in its gross margin to 55.2%, and it saw its operating margin cut nearly in half as the company spent heavily to race to catch up to its rivals in advanced computer chips. Analysts at Citigroup commented yesterday that Intel stock appears to be close to its peak valuation and is likely to decline as investors acclimate to the new environment in which Intel is losing, not gaining, market share.And the reason this is good news for AMD is that, according to Citi at least, it's AMD that's taking that market share away from Intel.Now whatSo what's an investor to do with all this information?At a valuation of just 13.6 times trailing earnings, Intel stock certainly looks like a relative bargain when compared with AMD stock, which trades at 38.4 times earnings. But AMD has acash-rich balance sheet, versus Intel that's carrying $13.5 billion in net debt. And analysts see Intel's earnings growing only 10% annually over the next five years, while AMD is pegged for 29.5% annualized earnings growth, according toS&P Global Market Intelligencedata.Intel may look like a value stockright now, but it's AMD that's gotall the momentum.","news_type":1,"symbols_score_info":{"AMD":0.9,"INTC":0.9}},"isVote":1,"tweetType":1,"viewCount":303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891650118,"gmtCreate":1628388100434,"gmtModify":1631889789559,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Like &amp; comment, please………👆🏻🙏🏻","listText":"Like &amp; comment, please………👆🏻🙏🏻","text":"Like & comment, please………👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/891650118","repostId":"1180529438","repostType":4,"repost":{"id":"1180529438","kind":"news","pubTimestamp":1628386129,"share":"https://www.laohu8.com/m/news/1180529438?lang=&edition=full","pubTime":"2021-08-08 09:28","market":"us","language":"en","title":"SEC Moves First DeFi Unregistered Securities Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=1180529438","media":"Benzinga","summary":"The United States Securities and Exchange Commission  sued the organization responsible for the development of a decentralized finance  protocol over activities involved with the project for the first time.What Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purported","content":"<div>\n<p>The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">Web Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SEC Moves First DeFi Unregistered Securities Lawsuit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSEC Moves First DeFi Unregistered Securities Lawsuit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-08 09:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180529438","content_text":"The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project for the first time.\nWhat Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purportedly sold over $30 million worth of two types of tokens that the SEC deemed to be securities that should have been registered as such.\nThe SEC notes that Blockchain Credit Partners founders Gregory Keough and Derek Acree will have to pay fines of $125,000 while the company itself also agreed to pay $12.8 million in disgorgement. The settlement does not indicate an admition or denial the accusations.\nNew Game, Old Rules?\nSEC Enforcement Director Gurbir Grewal explained that \"full and honest disclosure remains the cornerstone of our securities laws — no matter what technologies are used to offer and sell those securities.\" This comment makes it very clear that slapping the DeFi label on a project and hoping to avoid regulation this way works no better than calling it a \"utility token\" prevented falling under the SEC's scrutiny during 2017's initial coin offering craze.\nThe SEC is trying to send the clear rule that the new kind of financial organizations that operate on blockchains have to still play by the old rules that govern traditional finance. At the same time, market onlookers are not sure if the regulator is actually right.\nIn a way, it is a tour de force where the regulator wins every time it has a way to take enforcement action, but these new organizations potentially have a very real way to make enforcement impossible — or at the very least impractical. The only protection against enforcement by the SEC and other regulators is decentralization and the only reason why the SEC was able to act in this case is that a centralized organization such as Blockchain Credit Partners exists.\nWhat's Next:If no company exists and all that there is to a DeFi protocol is a set of smart contracts deployed on a blockchain by a group of anonymous developers scattered around the world there is very little that the SEC can do short of attacking the blockchain itself. This is where the decentralization of the underlying blockchain comes into play: will the regulators for instance be able to force Ethereum's (CRYPTO: ETH) core development team to write an update stopping such a project?\nIf the regulators would actually be able to force the blockchain's developers to write such an update, would node operators and miners or stakers adopt this software or would they refuse to? Such situations will be the real test of the decentralization and reliability of any blockchain that many are waiting to happen. Regulators are seeing power slipping away between their fingers like sand, and they are going to try to grab it.","news_type":1,"symbols_score_info":{"COIN":0.9}},"isVote":1,"tweetType":1,"viewCount":1476,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802510374,"gmtCreate":1627787223898,"gmtModify":1631889789570,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Please like and comment 🙏🏻","listText":"Please like and comment 🙏🏻","text":"Please like and comment 🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/802510374","repostId":"1159296868","repostType":4,"isVote":1,"tweetType":1,"viewCount":1482,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344773698,"gmtCreate":1618446449514,"gmtModify":1634292911898,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"It’s temporary 🦾","listText":"It’s temporary 🦾","text":"It’s temporary 🦾","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/344773698","repostId":"1189551384","repostType":4,"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":608534193,"gmtCreate":1638756985400,"gmtModify":1638756985492,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608534193","repostId":"1125593879","repostType":4,"repost":{"id":"1125593879","kind":"news","pubTimestamp":1638756575,"share":"https://www.laohu8.com/m/news/1125593879?lang=&edition=full","pubTime":"2021-12-06 10:09","market":"us","language":"en","title":"Why Moderna Is the Biggest Winner From COVID Boosters So Far","url":"https://stock-news.laohu8.com/highlight/detail?id=1125593879","media":"Motley Fool","summary":"It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authoriz","content":"<p>It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson &amp; Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.</p>\n<p></p>\n<p>A little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.</p>\n<p></p>\n<p>Which vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects</p>\n<p><b>Analyzing the data</b></p>\n<p>More booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&amp;J boosters. Pfizer and BioNTech are clearly in the lead on this front.</p>\n<p></p>\n<p>You'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.</p>\n<p></p>\n<p>Also, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.</p>\n<p></p>\n<p>So why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.</p>\n<p></p>\n<p>First, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.</p>\n<p></p>\n<p>Second, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&amp;J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.</p>\n<p></p>\n<p>Third, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&amp;J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&amp;J booster.</p>\n<p></p>\n<p><b>Why is Moderna winning?</b></p>\n<p>We don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.</p>\n<p></p>\n<p>My hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson &amp; Johnson vaccines. The initial efficacy of the single-shot J&amp;J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.</p>\n<p></p>\n<p>I suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.</p>\n<p></p>\n<p><b>What really matters</b></p>\n<p>Don't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.</p>\n<p></p>\n<p>What really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Is the Biggest Winner From COVID Boosters So Far</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Is the Biggest Winner From COVID Boosters So Far\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 10:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/05/why-moderna-is-the-biggest-winner-from-covid-boost/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/05/why-moderna-is-the-biggest-winner-from-covid-boost/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/12/05/why-moderna-is-the-biggest-winner-from-covid-boost/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125593879","content_text":"It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson & Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.\n\nA little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.\n\nWhich vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects\nAnalyzing the data\nMore booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&J boosters. Pfizer and BioNTech are clearly in the lead on this front.\n\nYou'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.\n\nAlso, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.\n\nSo why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.\n\nFirst, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.\n\nSecond, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.\n\nThird, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&J booster.\n\nWhy is Moderna winning?\nWe don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.\n\nMy hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson & Johnson vaccines. The initial efficacy of the single-shot J&J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.\n\nI suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.\n\nWhat really matters\nDon't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.\n\nWhat really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2776,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":349868988,"gmtCreate":1617589262544,"gmtModify":1634297709423,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"[得意]&nbsp;[财迷]&nbsp;[笑哭]&nbsp;","listText":"[得意]&nbsp;[财迷]&nbsp;[笑哭]&nbsp;","text":"[得意] [财迷] [笑哭]","images":[{"img":"https://static.tigerbbs.com/dec358618f34345ab53891ca61fd409a","width":"1125","height":"1107"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/349868988","isVote":1,"tweetType":1,"viewCount":1567,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":382396902,"gmtCreate":1613358787706,"gmtModify":1634553867761,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Hope it happens","listText":"Hope it happens","text":"Hope it happens","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/382396902","repostId":"2110204192","repostType":4,"isVote":1,"tweetType":1,"viewCount":500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344779970,"gmtCreate":1618446346490,"gmtModify":1634292913070,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Pls help&nbsp;comment and like 🙏🏻","listText":"Pls help&nbsp;comment and like 🙏🏻","text":"Pls help comment and like 🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/344779970","repostId":"1150191459","repostType":4,"isVote":1,"tweetType":1,"viewCount":168,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":327113538,"gmtCreate":1616068912424,"gmtModify":1634527409178,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Way to go!","listText":"Way to go!","text":"Way to go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/327113538","repostId":"1141211447","repostType":4,"repost":{"id":"1141211447","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1616067847,"share":"https://www.laohu8.com/m/news/1141211447?lang=&edition=full","pubTime":"2021-03-18 19:44","market":"us","language":"en","title":"Legend Biotech EPS beats by $0.08, beats on revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=1141211447","media":"Tiger Newspress","summary":"(March 18) Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business U","content":"<p>(March 18)&nbsp;Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update.</p>\n<ul>\n <li>Legend Biotech&nbsp;: Q4 GAAP EPS of -$0.22beats by $0.08.</li>\n <li>Revenue of $40.78M (+109.7% Y/Y)beats by $28.78M.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/03aed76701fd868589414ae62671e72a\" tg-width=\"685\" tg-height=\"498\"></p>\n<p><b>Financial Results for the Quarter and Year Ended December 31, 2020</b></p>\n<p>Cash and Cash Equivalents and time deposits:</p>\n<p>As of December 31, 2020, Legend Biotech had approximately $455.7 million of cash and cash equivalents and approximately $50.0 million in time deposits.</p>\n<p><b>Revenue</b></p>\n<p>Revenue for the three months ended December 31, 2020 was $40.8 million compared to $19.5 million for the three months ended December 31, 2019. The increase of $21.3 million was primarily due to revenue recognition of additional milestone payment achieved of higher amount pursuant to Legend Biotech’s agreement with Janssen and the associated constrained variable consideration is relieved. Revenue for the year ended December 31, 2020 was $75.7 million compared to $57.3 million for the year ended December 31, 2019. Similarly, the increase of $18.4 million for the year ended December 31, 2020 was primarily driven by revenue recognized from an additional milestone achieved of higher amount. Legend Biotech has not generated any revenue from product sales to date.</p>\n<p><b>Research and Development Expenses</b></p>\n<p>Research and development expenses for the three months ended December 31, 2020 were $66.9 million compared to $66.1 million for the three months ended December 31, 2019. This increase of $0.8 million was primarily due to an increase in employee benefit expense and research and development expense, net-off by a decrease in collaborative research and development expenses. Research and development expenses for the year ended December 31, 2020 was $232.2 million compared to $161.9 million for the year ended December 31, 2019 with a $70.3 million increase. The year-over-year increase was primarily due to a higher number of clinical trials, a higher number of patients enrolled in those trials and a higher number of research and development product candidates in the year ended December 31, 2020.</p>\n<p><b>Loss for the Period</b></p>\n<p>For the three months ended December 31, 2020, net loss was $57.8 million, or $0.22 per share, compared to a net loss of $63.9 million, or $0.32 per share, for the three months ended December 31, 2019. Net loss was $303.5 million, or $1.28 per share, for the year ended December 31, 2020 compared to $133.0 million, or $0.66 per share, for the year ended December 31, 2019.</p>\n<p>Key Upcoming Milestones</p>\n<ul>\n <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a MAA for cilta-cel for the treatment of adults with RRMM to the EMA in the first half of 2021.</li>\n <li>Legend Biotech intends to use the data from the CARTIFAN-1 study in support of a regulatory submission to the China Center for Drug Evaluation (CDE) seeking approval of cilta-cel for the treatment of adults with RRMM. Legend Biotech expects the submission of the application to occur in the second half of 2021.</li>\n <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a New Drug Application (NDA) to the Japan Ministry of Health, Labor and Welfare (JMHLW) in the second half of 2021 seeking approval of cilta-cel for the treatment of adults with RRMM.</li>\n <li>Legend Biotech expects to initiate its Phase 1 clinical trial of LB1901 in RR TCL inthe United Statesin 2021.</li>\n <li>Legend Biotech, in collaboration with Janssen, intends to present updated data from the CARTITUDE-1 and data from CARTITUDE-2 studies at major medical conferences in 2021.</li>\n <li>Legend Biotech anticipates supporting investigators with publishing a clinical data update from LEGEND-2 study in 2021.</li>\n</ul>\n<p>As the global COVID-19 pandemic continues to evolve, Legend Biotech has continuously monitored the situation in regards to its operations and has put significant measures in place to protect supply chain, operations, employees and the execution of clinical trials. Given the dynamic global situation, Legend Biotech notes that certain clinical trial timelines may be impacted.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech EPS beats by $0.08, beats on revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech EPS beats by $0.08, beats on revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-03-18 19:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(March 18)&nbsp;Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update.</p>\n<ul>\n <li>Legend Biotech&nbsp;: Q4 GAAP EPS of -$0.22beats by $0.08.</li>\n <li>Revenue of $40.78M (+109.7% Y/Y)beats by $28.78M.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/03aed76701fd868589414ae62671e72a\" tg-width=\"685\" tg-height=\"498\"></p>\n<p><b>Financial Results for the Quarter and Year Ended December 31, 2020</b></p>\n<p>Cash and Cash Equivalents and time deposits:</p>\n<p>As of December 31, 2020, Legend Biotech had approximately $455.7 million of cash and cash equivalents and approximately $50.0 million in time deposits.</p>\n<p><b>Revenue</b></p>\n<p>Revenue for the three months ended December 31, 2020 was $40.8 million compared to $19.5 million for the three months ended December 31, 2019. The increase of $21.3 million was primarily due to revenue recognition of additional milestone payment achieved of higher amount pursuant to Legend Biotech’s agreement with Janssen and the associated constrained variable consideration is relieved. Revenue for the year ended December 31, 2020 was $75.7 million compared to $57.3 million for the year ended December 31, 2019. Similarly, the increase of $18.4 million for the year ended December 31, 2020 was primarily driven by revenue recognized from an additional milestone achieved of higher amount. Legend Biotech has not generated any revenue from product sales to date.</p>\n<p><b>Research and Development Expenses</b></p>\n<p>Research and development expenses for the three months ended December 31, 2020 were $66.9 million compared to $66.1 million for the three months ended December 31, 2019. This increase of $0.8 million was primarily due to an increase in employee benefit expense and research and development expense, net-off by a decrease in collaborative research and development expenses. Research and development expenses for the year ended December 31, 2020 was $232.2 million compared to $161.9 million for the year ended December 31, 2019 with a $70.3 million increase. The year-over-year increase was primarily due to a higher number of clinical trials, a higher number of patients enrolled in those trials and a higher number of research and development product candidates in the year ended December 31, 2020.</p>\n<p><b>Loss for the Period</b></p>\n<p>For the three months ended December 31, 2020, net loss was $57.8 million, or $0.22 per share, compared to a net loss of $63.9 million, or $0.32 per share, for the three months ended December 31, 2019. Net loss was $303.5 million, or $1.28 per share, for the year ended December 31, 2020 compared to $133.0 million, or $0.66 per share, for the year ended December 31, 2019.</p>\n<p>Key Upcoming Milestones</p>\n<ul>\n <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a MAA for cilta-cel for the treatment of adults with RRMM to the EMA in the first half of 2021.</li>\n <li>Legend Biotech intends to use the data from the CARTIFAN-1 study in support of a regulatory submission to the China Center for Drug Evaluation (CDE) seeking approval of cilta-cel for the treatment of adults with RRMM. Legend Biotech expects the submission of the application to occur in the second half of 2021.</li>\n <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a New Drug Application (NDA) to the Japan Ministry of Health, Labor and Welfare (JMHLW) in the second half of 2021 seeking approval of cilta-cel for the treatment of adults with RRMM.</li>\n <li>Legend Biotech expects to initiate its Phase 1 clinical trial of LB1901 in RR TCL inthe United Statesin 2021.</li>\n <li>Legend Biotech, in collaboration with Janssen, intends to present updated data from the CARTITUDE-1 and data from CARTITUDE-2 studies at major medical conferences in 2021.</li>\n <li>Legend Biotech anticipates supporting investigators with publishing a clinical data update from LEGEND-2 study in 2021.</li>\n</ul>\n<p>As the global COVID-19 pandemic continues to evolve, Legend Biotech has continuously monitored the situation in regards to its operations and has put significant measures in place to protect supply chain, operations, employees and the execution of clinical trials. Given the dynamic global situation, Legend Biotech notes that certain clinical trial timelines may be impacted.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LEGN":"传奇生物"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141211447","content_text":"(March 18) Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update.\n\nLegend Biotech : Q4 GAAP EPS of -$0.22beats by $0.08.\nRevenue of $40.78M (+109.7% Y/Y)beats by $28.78M.\n\n\nFinancial Results for the Quarter and Year Ended December 31, 2020\nCash and Cash Equivalents and time deposits:\nAs of December 31, 2020, Legend Biotech had approximately $455.7 million of cash and cash equivalents and approximately $50.0 million in time deposits.\nRevenue\nRevenue for the three months ended December 31, 2020 was $40.8 million compared to $19.5 million for the three months ended December 31, 2019. The increase of $21.3 million was primarily due to revenue recognition of additional milestone payment achieved of higher amount pursuant to Legend Biotech’s agreement with Janssen and the associated constrained variable consideration is relieved. Revenue for the year ended December 31, 2020 was $75.7 million compared to $57.3 million for the year ended December 31, 2019. Similarly, the increase of $18.4 million for the year ended December 31, 2020 was primarily driven by revenue recognized from an additional milestone achieved of higher amount. Legend Biotech has not generated any revenue from product sales to date.\nResearch and Development Expenses\nResearch and development expenses for the three months ended December 31, 2020 were $66.9 million compared to $66.1 million for the three months ended December 31, 2019. This increase of $0.8 million was primarily due to an increase in employee benefit expense and research and development expense, net-off by a decrease in collaborative research and development expenses. Research and development expenses for the year ended December 31, 2020 was $232.2 million compared to $161.9 million for the year ended December 31, 2019 with a $70.3 million increase. The year-over-year increase was primarily due to a higher number of clinical trials, a higher number of patients enrolled in those trials and a higher number of research and development product candidates in the year ended December 31, 2020.\nLoss for the Period\nFor the three months ended December 31, 2020, net loss was $57.8 million, or $0.22 per share, compared to a net loss of $63.9 million, or $0.32 per share, for the three months ended December 31, 2019. Net loss was $303.5 million, or $1.28 per share, for the year ended December 31, 2020 compared to $133.0 million, or $0.66 per share, for the year ended December 31, 2019.\nKey Upcoming Milestones\n\nLegend Biotech’s collaborator, Janssen, anticipates submitting a MAA for cilta-cel for the treatment of adults with RRMM to the EMA in the first half of 2021.\nLegend Biotech intends to use the data from the CARTIFAN-1 study in support of a regulatory submission to the China Center for Drug Evaluation (CDE) seeking approval of cilta-cel for the treatment of adults with RRMM. Legend Biotech expects the submission of the application to occur in the second half of 2021.\nLegend Biotech’s collaborator, Janssen, anticipates submitting a New Drug Application (NDA) to the Japan Ministry of Health, Labor and Welfare (JMHLW) in the second half of 2021 seeking approval of cilta-cel for the treatment of adults with RRMM.\nLegend Biotech expects to initiate its Phase 1 clinical trial of LB1901 in RR TCL inthe United Statesin 2021.\nLegend Biotech, in collaboration with Janssen, intends to present updated data from the CARTITUDE-1 and data from CARTITUDE-2 studies at major medical conferences in 2021.\nLegend Biotech anticipates supporting investigators with publishing a clinical data update from LEGEND-2 study in 2021.\n\nAs the global COVID-19 pandemic continues to evolve, Legend Biotech has continuously monitored the situation in regards to its operations and has put significant measures in place to protect supply chain, operations, employees and the execution of clinical trials. Given the dynamic global situation, Legend Biotech notes that certain clinical trial timelines may be impacted.","news_type":1,"symbols_score_info":{"LEGN":0.9}},"isVote":1,"tweetType":1,"viewCount":250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":369247330,"gmtCreate":1614052823920,"gmtModify":1634551384439,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"[流泪]&nbsp;","listText":"[流泪]&nbsp;","text":"[流泪]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/369247330","repostId":"1174723019","repostType":4,"repost":{"id":"1174723019","kind":"news","pubTimestamp":1614051562,"share":"https://www.laohu8.com/m/news/1174723019?lang=&edition=full","pubTime":"2021-02-23 11:39","market":"us","language":"en","title":"Why Tesla Stock Fell Sharply on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1174723019","media":"Motley Fool","summary":"Most of the stock's gain this year has been erased.\nWhat happened\nShares of Tesla(NASDAQ:TSLA) were ","content":"<p>Most of the stock's gain this year has been erased.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Tesla</b>(NASDAQ:TSLA)&nbsp;were pummeled on Monday. The stock closed the trading day down about 8.6%</p>\n<p>The automaker's stock decline was likely primarily due to a pullback in the overall market on Monday. Many&nbsp;growth stocks&nbsp;like Tesla were hit particularly hard.</p>\n<p><b>So what</b></p>\n<p>Volatility should be expected from Tesla stock. It soared 743% last year as it won over Wall Street's attention. Tesla's sales jumped, and the company demonstrated strong profits. Also likely helping the stock price last year was a big year for growth stocks in general. Many such stocks soared 50% or more in 2020.</p>\n<p>But growth stocks were taking a breather on Monday as the&nbsp;<b>Nasdaq Composite</b>&nbsp;fell 2.5%.</p>\n<p>Most of Tesla's gains this year have evaporated. Shares are now up just 1.5% in 2021.</p>\n<p><b>Now what</b></p>\n<p>Tesla's underlying business will likely continue to grow rapidly this year. Indeed, management guided for vehicle deliveries to increase from about 500,000 in 2020 to more than 750,000 this year.</p>\n<p>But with a very optimistic business view already priced into Tesla shares, it's difficult to predict where the stock could end up at the end of 2021.</p>\n<p>There's one thing we can expect with near certainty: plenty more volatility.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Tesla Stock Fell Sharply on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Tesla Stock Fell Sharply on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-23 11:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/02/22/why-tesla-stock-fell-sharply-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Most of the stock's gain this year has been erased.\nWhat happened\nShares of Tesla(NASDAQ:TSLA) were pummeled on Monday. The stock closed the trading day down about 8.6%\nThe automaker's stock decline ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/02/22/why-tesla-stock-fell-sharply-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.fool.com/investing/2021/02/22/why-tesla-stock-fell-sharply-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174723019","content_text":"Most of the stock's gain this year has been erased.\nWhat happened\nShares of Tesla(NASDAQ:TSLA) were pummeled on Monday. The stock closed the trading day down about 8.6%\nThe automaker's stock decline was likely primarily due to a pullback in the overall market on Monday. Many growth stocks like Tesla were hit particularly hard.\nSo what\nVolatility should be expected from Tesla stock. It soared 743% last year as it won over Wall Street's attention. Tesla's sales jumped, and the company demonstrated strong profits. Also likely helping the stock price last year was a big year for growth stocks in general. Many such stocks soared 50% or more in 2020.\nBut growth stocks were taking a breather on Monday as the Nasdaq Composite fell 2.5%.\nMost of Tesla's gains this year have evaporated. Shares are now up just 1.5% in 2021.\nNow what\nTesla's underlying business will likely continue to grow rapidly this year. Indeed, management guided for vehicle deliveries to increase from about 500,000 in 2020 to more than 750,000 this year.\nBut with a very optimistic business view already priced into Tesla shares, it's difficult to predict where the stock could end up at the end of 2021.\nThere's one thing we can expect with near certainty: plenty more volatility.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2030,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":382391303,"gmtCreate":1613358439602,"gmtModify":1634553868957,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Useful","listText":"Useful","text":"Useful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/382391303","repostId":"2110026963","repostType":4,"isVote":1,"tweetType":1,"viewCount":346,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164051645,"gmtCreate":1624162333087,"gmtModify":1631889789608,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"🙏🏻🙏🏻🙏🏻","listText":"🙏🏻🙏🏻🙏🏻","text":"🙏🏻🙏🏻🙏🏻","images":[{"img":"https://static.tigerbbs.com/d8dd96436bea0b9c92dd95ae16e70361","width":"1125","height":"1074"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164051645","isVote":1,"tweetType":1,"viewCount":1687,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":166010936,"gmtCreate":1623985232225,"gmtModify":1631889789623,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Read the safety before flying to the moon 🚀🚀🚀","listText":"Read the safety before flying to the moon 🚀🚀🚀","text":"Read the safety before flying to the moon 🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/bf7f199d98279f47b434137f93979947","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166010936","isVote":1,"tweetType":1,"viewCount":1216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":161971406,"gmtCreate":1623902995605,"gmtModify":1631889789642,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"一分一毫 清清楚楚","listText":"一分一毫 清清楚楚","text":"一分一毫 清清楚楚","images":[{"img":"https://static.tigerbbs.com/2df10f85bb15a2fd54fd84fa66c51782","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161971406","isVote":1,"tweetType":1,"viewCount":1949,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":169061156,"gmtCreate":1623809414075,"gmtModify":1631889789654,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"Lastly, buy!","listText":"Lastly, buy!","text":"Lastly, buy!","images":[{"img":"https://static.tigerbbs.com/977ef722d3398baaae16beac29e882c8","width":"720","height":"720"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169061156","isVote":1,"tweetType":1,"viewCount":1279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":185908820,"gmtCreate":1623629234460,"gmtModify":1631889789662,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559395309338899","authorIdStr":"3559395309338899"},"themes":[],"htmlText":"🙏🏻🙏🏻🙏🏻","listText":"🙏🏻🙏🏻🙏🏻","text":"🙏🏻🙏🏻🙏🏻","images":[{"img":"https://static.tigerbbs.com/810dfc226dde7db2efc68b3b69c713e8","width":"1125","height":"1100"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185908820","isVote":1,"tweetType":1,"viewCount":645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}